BCIQ Profiles

Company Profile Report
0408 ECP ValenzaBio EMB 7am ET
BioCentury & Getty Images

Emerging Company Profile

Crossovers Fidelity, Surveyor invest early in ValenzaBio, backing $70M series A for rare autoimmune play

Emerging Company Profile: ValenzaBio readies to take mAbs from CRUK, Pierre Fabre into clinic

After landing mAbs from CRUK and Pierre Fabre, ValenzaBio prepares to challenge established players in autoimmune and inflammatory conditions. 

Apr 8, 2021 | 11:02 AM GMT

With a $70 million series A round led by Fidelity in a syndicate that included crossover Surveyor, start-up ValenzaBio is readying to take antibodies licensed from CRUK and Pierre Fabre into early clinical testing for rare autoimmune

Read the full 1004 word article

How to gain access

Continue reading with a
two-week free trial.